Literature DB >> 12101135

Being economical with the truth: how to make your idea appear cost effective.

S Goodacre1, C McCabe.   

Abstract

Mesh：

Year:  2002        PMID： 12101135      PMCID： PMC1725899          DOI： 10.1136/emj.19.4.301

Source DB:  PubMed          Journal:  Emerg Med J        ISSN： 1472-0205            Impact factor:   2.740


× No keyword cloud information.
  14 in total

1.  Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities.

Authors:  P C Langley
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

Review 2.  Reporting on quality of life in randomised controlled trials: bibliographic study.

Authors:  C Sanders; M Egger; J Donovan; D Tallon; S Frankel
Journal:  BMJ       Date:  1998-10-31

3.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

4.  Early mobilization of acute whiplash injuries.

Authors:  K Mealy; H Brennan; G C Fenelon
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08

5.  Acute treatment of whiplash neck sprain injuries. A randomized trial of treatment during the first 14 days after a car accident.

Authors:  G E Borchgrevink; A Kaasa; D McDonagh; T C Stiles; O Haraldseth; I Lereim
Journal:  Spine (Phila Pa 1976)       Date:  1998-01-01       Impact factor: 3.468

6.  The role of physiotherapy in the management of acute neck sprains following road-traffic accidents.

Authors:  L A McKinney; J O Dornan; M Ryan
Journal:  Arch Emerg Med       Date:  1989-03

7.  Economic evaluation and health care. What does it mean?

Authors:  R Robinson
Journal:  BMJ       Date:  1993-09-11

8.  Cost-effectiveness analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-09-25

9.  Early mobilisation and outcome in acute sprains of the neck.

Authors:  L A McKinney
Journal:  BMJ       Date:  1989-10-21

10.  Cost-utility analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-10-02
View more
  11 in total

1.  How to change clinical behaviour: no answers yet.

Authors:  David Jewell
Journal:  Br J Gen Pract       Date:  2003-04       Impact factor: 5.386

2.  Efforts to ban direct-to-consumer advertising in New Zealand: a call to action.

Authors:  Jerome R Hoffman; Richelle J Cooper
Journal:  Br J Gen Pract       Date:  2003-04       Impact factor: 5.386

3.  Confidentiality: consent is not sufficient.

Authors:  Paul Thornton
Journal:  Br J Gen Pract       Date:  2003-04       Impact factor: 5.386

4.  Transparency in economic evaluations.

Authors:  Suzanne Hill
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Authors:  Jaclyn Beca; Don Husereau; Kelvin K W Chan; Neil Hawkins; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

Review 6.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

7.  Economical analysis on prophylaxis, diagnosis, and treatment of periprosthetic infections.

Authors:  Mariano Fernandez-Fairen; Ana Torres; Ann Menzie; Daniel Hernandez-Vaquero; José Manuel Fernandez-Carreira; Antonio Murcia-Mazon; Enrique Guerado; Luis Merzthal
Journal:  Open Orthop J       Date:  2013-06-14

8.  Model Registration: A Call to Action.

Authors:  Christopher James Sampson; Tim Wrightson
Journal:  Pharmacoecon Open       Date:  2017-06

9.  The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.

Authors:  Seamus Kent; Frauke Becker; Talitha Feenstra; An Tran-Duy; Iryna Schlackow; Michelle Tew; Ping Zhang; Wen Ye; Shi Lizheng; William Herman; Phil McEwan; Wendelin Schramm; Alastair Gray; Jose Leal; Mark Lamotte; Michael Willis; Andrew J Palmer; Philip Clarke
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 10.  When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.

Authors:  Ferrán Catalá-López; Gabriel Sanfélix-Gimeno; Manuel Ridao; Salvador Peiró
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.